Research programme: haem oxygenase-1 inhibitors - Selvita

Drug Profile

Research programme: haem oxygenase-1 inhibitors - Selvita

Alternative Names: SEL303

Latest Information Update: 11 Nov 2014

Price : $50

At a glance

  • Originator Selvita
  • Class
  • Mechanism of Action Decyclizing heme oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 11 Nov 2014 Early research in Solid tumours in Poland (unspecified route)
  • 11 Nov 2014 Early research in Haematological malignancies in Poland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top